Italia Markets open in 1 hr 58 mins
Dow Jones
32.394,25 -37,83 (-0,12%) Nasdaq
11.716,08 -52,76 (-0,45%) Nikkei 225
27.719,84 +201,59 (+0,73%) EUR/USD
1,0842 -0,0005 (-0,0434%) BTC-EUR
25.441,58 +573,82 (+2,31%) CMC Crypto 200
605,14 +362,46 (+149,36%)
Blueprint Medicines Corporation (BPMC)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Dopo ore:
| Chiusura precedente | 43,32 |
| Aperto | 43,15 |
| Denaro | 0,00 x 1800 |
| Lettera | 0,00 x 900 |
| Min-Max giorno | 42,40 - 43,67 |
| Intervallo di 52 settimane | 37,82 - 79,40 |
| Volume | |
| Media Volume | 575.903 |
| Capitalizzazione | 2,547B |
| Beta (5 anni mensile) | 0,64 |
| Rapporto PE (ttm) | 7,53 |
| EPS (ttm) | 5,66 |
| Prossima data utili | 01 mag 2023 - 05 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 75,53 |
- GlobeNewswire
Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million
Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based m
© 2023 Yahoo. Tutti i diritti riservati.
